ArticleAspirin and Colorectal Cancer: The PIK3CA Trial Explained
The ALASCCA trial found low-dose aspirin cut colorectal cancer recurrence in tumors with PI3K pathway changes. Here is what it shows and the bleeding risks.
2 matches across articles, videos and resources.
ArticleThe ALASCCA trial found low-dose aspirin cut colorectal cancer recurrence in tumors with PI3K pathway changes. Here is what it shows and the bleeding risks.
Video: the ALASCCA trial found low-dose aspirin lowered 3-year colorectal cancer recurrence in tumors with PIK3CA changes. Includes the bleeding risks.